size effici drug distributor
updat forecast estim
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research
estim
price data jan
rate updat jan
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
play critic role pharmaceut
suppli chain decad come perspect firm
stand premier player believ possess wide
econom moat thank coloss scale firm key cogs
pharmaceut industri mani supply-chain
particip depend servic streamlin product
distribut procur anticip robust growth
pharmaceut industri long term provid
firm solid platform continu success
one three
distributor main supplier larg pharmaci outlet
walgreen express script mail order pharmaci firm
highli integr strateg agreement walgreen
suppli retail pharmaci drug inventori includ
gener last aspect key -- suppli higher-margin gener
drug one biggest gener drug retail outlet major
posit profit capit effici invest capit return
cours fiscal manag team
excel job integr approxim store
distribut oper believ reflect strong scale
leverag effici built last
addit opportun
procur gener inventori alreadi coloss walgreen
boot allianc develop dynam enabl drug
distributor obtain gener inventori lower cost level
firm also major specialti drug distributor
posit favor benefit fastest-grow drug
categori pharmaceut market
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
one three major pharmaceut distributor
unit state top-tier distribut asset activ includ
forecast logist servic firm also wholesal leader
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fair valu estim per share account
amerisourc recent acquisit smith midtier
drug distributor solid growth walgreen
partnership slight mix shift toward higher-pr
specialti pharmaceut product amerisourc done
excel job drive organ revenu growth
ramp complex walgreen partnership great
effici firm also posit well
fast-grow specialti drug distribut sector largest
distributor market factor drive solid
top-lin growth extend forecast period
addit solid revenu growth also anticip
increas capital-manag effici distributor
next sever year result increas
volum -- notabl integr walgreen
partnership amerisourc procur gener drug
suppli walgreen boot allianc partnership
obtain gener drug inventori lower cost level
contribut outlook amerisourc confluenc
age popul influx previous uninsur
peopl healthcar market greater use
pharmaceut front-lin treatment provid
platform solid top- bottom-lin growth accordingli
factor five-year revenu compound
annual growth rate averag oper margin
explicit forecast
scenario analysi take consider effect
drug price volatil pharmaceut market growth
bull-cas scenario factor less price
pressur higher profit result also assum
abl exert even negoti
leverag given access walgreen boot allianc
gener sourc partnership addit factor
high-single-digit industri growth uptak drug
usag increas faster initi expect
scenario fair valu estim
increas
bear case assum increas price pressur
continu grow addit assum gener
sourc partnership walgreen
advantag addit discount
fail materi par current expect
scenario fair valu estim decreas per
moat perspect three major pharmaceut
distributor carv wide econom moat
coloss size unmatch effici give key
critic role among manufactur retail outlet
solidifi long-term outsiz return accord
center medicar medicaid servic estim
total retail pharmaceut spend littl
billion major spend flow
oper major three pharmaceut
robust
sustain econom profit player
estim cardin health
combin market share well
combin dynam slim industri profit keep new
entrant bay new player would tough time
carv enough share effici leverag
distribut asset posit econom profit
dynam solidifi long-term competit posit
major three drug distributor firm also obtain
deep price discount drug manufactur mani
custom acquir make
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
pharmaceut product provid excel long-term
tailwind firm addit amerisourc play
critic role pharmaceut industri main
sourc drug suppli signific portion retail
pharmaci outlet effici distributor drug
player essenti link pharmaceut suppli
critic massiv distribut oper
amerisourc mean enjoy excel asset effici
unparallel logist expertis driven decent
asset return howev abil effect manag
capit base true driver outsiz return drug
distributor firm produc top-tier asset turn cash
convers inventori manag metric
led outsiz return invest capit -- trend believ
last long term
despit recent drug price volatil shift market
dynam believ amerisourc stabl econom
moat trend perspect recent price
headwind near-term firm abl
overcom obstacl given entrench posit
global pharmaceut space demograph trend
skew older expans government-sponsor
healthcar coverag
increas spend
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
major pharmaceut
distributor billion annual revenu
coloss size make firm prefer partner
among major drug manufactur mani retail
opharmaceut spend continu grow
robustli next decad given demograph
shift expans medic insur
coverag current uninsur
specialti drug spend continu increas
believ distributor opportun captur
valu nich market improv top-
bottom-lin result
oprofit margin razor-thin
make signific price pressur major
effort procur cheaper suppli gener
product partner
walgreen enhanc negoti power
fixed-cost scale make firm reliant upon one
major custom signific amount revenu
profit
osal volum could take materi hit
feder govern implement scaled-back
healthcar legisl price control
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
amerisourc good financi health
continu prudent capital-alloc polici
strong free cash product oper keep
amerisourc solid financi situat long term
surround drug price repeal afford
act concert push mani
pharmaceut stakehold institut govern
control drug price scenario drug
distributor could face prospect government-dict
profit addit current legitim
push congress repeal key provis
certain mandat scale back drug wholesal
would probabl see lower volum moder headwind
posit scale dynam
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
believ stewardship
larg posit sharehold oper execut
capit manag benefici econom
profit firm signific distribut gener
sourc partnership agreement walgreen part
agreement enabl walgreen boot allianc
acquir approxim equiti
balanc believ manag made right
strateg move agreement make amerisourcebergen
exclus drug supplier one world largest
retail pharmaci agreement also give
distributor access advantag gener drug
price firm also servic express script mail order
contract contract yield lower level
profit roic gain scale effici
econom posit past sever year
manag built amerisourcebergen
powerhous specialti drug nich put firm
highli
board director
repres date owner name posit common share held report holder issuer
new york mellon corp
share
fund
share
fund
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
amerisourc report mix quarter oper
amerisourc report mix quarter main
take-away continu stabil core drug
distribut oper fact specialti distribut
oper seem hit cylind amerisourc
largest specialti distributor believ
solid result segment major posit price
volatil core pharmaceut distribut busi
remain stabl posit sign addit
manag mention abl smoothli finish
integr believ recent infrastructur
invest begun payoff contribut
greater distribut effici find develop
encourag reiter fair valu
estim wide moat rate amerisourc also recent
distributor earlier year integr process
asset correspond client book ad
materi result believ solid oper
move add firm top-tier distribut
asset grow client book enhanc wide econom
case last quarter materi
headwind amerisourc non-drug wholes
busi particular continu major
headwind relat firm drug compound
manufactur key
facil close given
manufactur concern rais recent fda
inspect cost bring facil par
major drag result firm uncertain
abl bring asset back on-line accordingli
manag gave conserv outlook
guidanc leeri acquisit fall
outsid core distribut oper concern
born given struggl pharmedium
segment nevertheless pleas manag
chosen refocu firm back toward optim
pharmaceut distribut oper institut
billion share repurchas program along increas
dividend believ capit alloc strategi
better sharehold
stabil oper environ aug
even though may materi chang
variou part pharmaceut market oper
next sever year need sourc deliv
drug cost-effect effici manner
chang believ fundament factor form
strong foundat core drug
wholes oper need drug
manufactur retail pharmaci matter
market dynam shift thu reiter wide-
moat rate fair valu estim drug
continu stabil core drug distribut
oper believ firm price environ
improv oper effici contribut decent
result maintain gener
deflat expect confid lower brand gross
oper brand manufactur agreement
fee-for-servic base
inflat outlook advers affect
quarter amerisourc report rel solid result
gross profit remain flat off-set moder
increas central cost net result
basis-point decreas adjust oper margin
pressur result firm realign
pharmedium compound manufactur lash group
consult busi factor issu
outlook model oper margin
firm core distribut busi fall fiscal
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
produc fiscal expect
profit begin expand begin fiscal
signific amount model drug
distribut oper margin expand moder
overal firm-wide oper margin increas
end fiscal believ repres
conserv outlook firm profit expans effort
perspect amerisourc perform
admir past quarter focu drive
much valu core drug distribut oper
believ firm posit extrem well long-
term think import investor factor
critic role drug distributor play oper
cardin health
essenti develop appeal drug
determin market demand product product runs/
inventori manag global distribut
servic larg compens fix fee
structur like remain scenario
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end septemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end septemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
